IRCT20090526001952N16 IRCT 2023-05-30 Tehran University of Medical Sciences Comparison of the effect of two methods of cabergoline administration to prevent ovarian hyperstimulation syndrome in women with polycystic ovary syndrome Comparison of the effect of two cabergoline administration methods to prevent ovarian hyperstimulation syndrome (OHSS) in patients with polycystic ovary syndrome (PCO) under IVF 2023-03-01 anticipated 200 Complete https://irct.ir/trial/70355 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Randomization description: Our sample size is 200 people, with 100 people in each group. The randomization method used in this study will be the block randomization method developed by the statistics expert by using the STATA software in a randomization list format. Then, according to the randomization list, the type of intervention for each individual will be written on paper, and the paper will be put in a sealed envelope. Envelopes will be numbered according to the randomization list. The physician will examine the patient's eligibility, and if the patient is eligible, she will tell the hospital research assistant. The research assistant will then provide the sealed envelope to the physician, and the physician will begin the intervention according to the contents of the envelope.or, Blinding description: Because of the kind of intervention, The patient will be aware of the treatment. Outcomes assessor will not be informed about the kind of treatment A statistician who is unaware of the type of interventions in each group will analyze the data. 3 Polycystic ovarian syndrome. Intervention 1: Intervention group1: At the same time as starting the GNRH antagonist, cabergoline 0.5 mg tablets (Aborihan Pharmaceuticals, Iran) are administered orally once a day for 15 days. Intervention 2: Intervention group2:In this group, at the same time as the trigger (GNRH agonist) begins, abergoline 0.5 mg tablets (Aborihan Pharmaceuticals, Iran) are administered orally once a day for 8 days. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is It is not yet known if there will be a plan to make this available